spacer
home > ict > spring 2021 > accelerating towards modern clinical trials
PUBLICATIONS
International Clinical Trials

Accelerating Towards Modern Clinical Trials



Companies are racing to develop vaccines and treatments for COVID-19, prompting industry-wide urgency to initiate and expedite new trials. Yet the need to keep existing trials on track to get medicines to patients remains, and these trials are being disrupted due to the pandemic. Over 976 companies have reported interruptions to clinical trials (1).

The lengthy process of conducting clinical research has come under the spotlight and needs to be addressed. Conducting a study today is no faster than it was a decade ago, averaging six to eight years to develop a new product. Paper-based documents and departmental silos are holding trials back. There’s tremendous innovation happening in the industry, but the inefficiency of using manual processes to get advanced therapies to market has been exposed.

The industry is rapidly modernising its systems and processes to improve collaboration across stakeholders and run faster studies. Sponsors, CROs, and sites are looking for simpler ways to share information and make it easier for patients to participate in new trials, from enrolment to treatment.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the Author

Rik van Mol is a Senior Executive at Veeva Systems with over 20 years of experience in both management consulting and cloud software in the life science/pharmaceutical sector. His experience has been built in assisting clients through complex transformation programmes across the life science value chain for most of the world’s largest companies. Rik is a recognised thought leader in the life science industry with deep expertise in architecting, launching, and implementing innovative and industry-leading strategies and solutions.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Bruker Presents High-Value Life Science, Materials Research and Applied Market Solutions at Analytica 2022

MUNICH, Germany - June 21, 2022: Bruker Corporation (Nasdaq: BRKR) this week displays its high-value scientific instrumentation, software and integrated solutions for applications in materials and energy research, biopharmaceuticals, applied markets, as well as life science and translational research at Analytica 2022.
More info >>

White Papers

Time lapse photography to demonstrate the potential antimicrobial abilities of Dycem contamination control flooring

Dycem

A defined volume of bioluminescent reporter bacteria was deposited onto 20 mm x 20 mm coupons of Dycem flooring, vinyl tile and ITW Alma tacky mat. Through monitoring of bacterial bioluminescence, metabolic inhibition was observed on all three surfaces however the effect occurred more rapidly on Dycem flooring than on vinyl or ITW Alma. Recovery counts after three hours of exposure to the floor surfaces showed between a 65% and 100% decrease in the number of viable organisms recovered from Dycem flooring compared to controls. On vinyl and ITW Alma flooring, there were slight increases in the number of viable survivors recovered compared to controls. Dycem flooring inhibited the metabolic activity and reduced the number of viable survivors recovered of Salmonella enterica Serovar Typhimurium DT104 pGLITE. It remains unclear as to whether this effect is attributable to the impregnated biocide or rapid drying of the inoculum on this surface.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement